226 related articles for article (PubMed ID: 20439609)
1. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Lanier ER; Ptak RG; Lampert BM; Keilholz L; Hartman T; Buckheit RW; Mankowski MK; Osterling MC; Almond MR; Painter GR
Antimicrob Agents Chemother; 2010 Jul; 54(7):2901-9. PubMed ID: 20439609
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
Painter GR; Almond MR; Trost LC; Lampert BM; Neyts J; De Clercq E; Korba BE; Aldern KA; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2007 Oct; 51(10):3505-9. PubMed ID: 17646420
[TBL] [Abstract][Full Text] [Related]
3. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
Hummert P; Parsons TL; Ensign LM; Hoang T; Marzinke MA
J Pharm Biomed Anal; 2018 Apr; 152():248-256. PubMed ID: 29433097
[TBL] [Abstract][Full Text] [Related]
4. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
6. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Margot NA; Johnson A; Miller MD; Callebaut C
Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Margot N; Ram R; Abram M; Haubrich R; Callebaut C
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
Ray AS; Fordyce MW; Hitchcock MJ
Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Duwal S; Schütte C; von Kleist M
PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.
Heredia A; Davis CE; Reitz MS; Le NM; Wainberg MA; Foulke JS; Wang LX; Redfield RR
J Infect Dis; 2013 Dec; 208(12):2085-94. PubMed ID: 23922365
[TBL] [Abstract][Full Text] [Related]
11. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Hoang T; Date AA; Ortiz JO; Young TW; Bensouda S; Xiao P; Marzinke M; Rohan L; Fuchs EJ; Hendrix C; Gumber S; Villinger F; Cone RA; Hanes J; Ensign LM
Eur J Pharm Biopharm; 2019 May; 138():23-29. PubMed ID: 29802984
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
Squires K; Pozniak AL; Pierone G; Steinhart CR; Berger D; Bellos NC; Becker SL; Wulfsohn M; Miller MD; Toole JJ; Coakley DF; Cheng A;
Ann Intern Med; 2003 Sep; 139(5 Pt 1):313-20. PubMed ID: 12965939
[TBL] [Abstract][Full Text] [Related]
15. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection.
Perry CM
Drugs; 2009; 69(7):843-57. PubMed ID: 19441871
[TBL] [Abstract][Full Text] [Related]
16. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
18. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
Ray AS; Myrick F; Vela JE; Olson LY; Eisenberg EJ; Borroto-Esodo K; Miller MD; Fridland A
Antivir Ther; 2005; 10(3):451-7. PubMed ID: 15918336
[TBL] [Abstract][Full Text] [Related]
19. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
White KL; Chen JM; Margot NA; Wrin T; Petropoulos CJ; Naeger LK; Swaminathan S; Miller MD
Antimicrob Agents Chemother; 2004 Mar; 48(3):992-1003. PubMed ID: 14982794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
